Stent Graft Market Size, Share & Trends Analysis | Global | 2025-2031 | Includes: AAA, FAA, and TAA Stent Grafts

Global Stent Graft Market Report

The global stent graft market was valued at $2.9 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 4.9% to reach $4.1 billion by 2032.

• The full report suite on the global market for stent grafts covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a clear view of future market trends and growth patterns. This description follows the same structure and best-practice flow used in the attached example document, adapted to the stent graft market and its specific competitive and clinical dynamics .

This report provides detailed analysis of the global stent graft market, including unit sales, procedure numbers, average selling prices, market shares, market size, growth trends and market forecasts through 2032, with historical data to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios, leading competitors, and qualitative analysis of the main forces shaping market expansion.

The market is being supported by the continued shift toward minimally invasive vascular treatment. Endovascular repair is increasingly preferred in many aortic procedures because it can reduce patient trauma, shorten hospital stays and support faster recovery when compared with open surgery. This shift is encouraging broader use of stent grafts in abdominal aortic aneurysm repair, thoracic endovascular aortic repair and more complex anatomies that previously had fewer minimally invasive treatment options.

Overall, the global stent graft market remains one of the more important growth areas in vascular intervention. It combines a large installed clinical need with strong innovation, expanding screening activity and continued movement toward less invasive aortic repair.

Market Overview

The global stent graft market includes implantable endovascular devices used to exclude aneurysms and repair diseased sections of the aorta and related vascular anatomy without requiring full open surgery. These devices are used most prominently in abdominal aortic aneurysm, thoracic aortic aneurysm and fenestrated or anatomically complex repair procedures. They represent a key part of the broader trend toward endovascular management of vascular disease.

This market has developed as physicians and healthcare systems increasingly favor less invasive treatment pathways where clinically appropriate. Compared with traditional surgical graft implantation, endovascular stent graft procedures can reduce operating time, limit blood loss, shorten hospital stays and support faster patient recovery. These advantages have made stent grafts an important option in many high-risk patients who may not tolerate open surgery as well.

The stent graft market also reflects the growing sophistication of vascular intervention. Earlier generations of devices had more limited anatomical applicability and lower flexibility. Today, manufacturers are investing in graft designs that can better accommodate difficult anatomies, more challenging access conditions and more specialized procedural needs. This includes ongoing development in thoracic, fenestrated and branched technologies, as well as improvements in delivery systems that make the procedure more manageable for physicians.

The result is a market that is mature in some areas, especially standard abdominal repair, but still expanding through newer technologies, improved screening, broader physician adoption and better treatment options for complex cases. This balance of established clinical need and continuing innovation is a major reason why the market is expected to grow steadily through 2032.

Market Drivers

TAA Stent Grafts

One of the most important drivers in the global stent graft market is the growth potential of thoracic aortic aneurysm stent grafts. The thoracic segment remains relatively newer than some abdominal applications and still has meaningful room for expansion. If indications such as dissections, ulcers and trauma continue to be incorporated into treatment pathways, the thoracic segment could represent a much larger share of the total market over time.

There is strong clinical demand in this segment because untreated thoracic aortic aneurysms carry a high risk. A meaningful proportion of thoracic patients historically went untreated because the surgical option was complex and risky. As thoracic endovascular aortic repair becomes more established and device design improves, more patients can be considered for minimally invasive treatment. This directly supports growth in TAA stent graft demand.

Further product development is also helping expand this segment. Lower-profile devices, better flexibility, improved trackability and branched thoracic platforms all increase the number of anatomies that can be treated endovascularly. These improvements support both unit growth and higher market value.

Long-Term Cost Efficiency

Another major market driver is the long-term cost efficiency of stent graft procedures. Although stent grafts are more expensive than surgical grafts at the device level, their overall economic value can still be attractive because patients often require shorter hospital stays. For hospitals with high patient turnover or pressure on inpatient capacity, this is an important advantage.

Open surgery can lead to longer recoveries and more resource-intensive hospital stays, especially when complications occur. Even when a stent graft has a higher initial price, the ability to reduce hospitalization time can offset part of that cost. This value proposition has helped support adoption in many developed markets and remains an important part of the commercial case for stent graft use.

Increased Aneurysm Screening

Greater aneurysm screening is also supporting market expansion. In some regions, especially parts of Europe, endovascular penetration rates remain lower than in other developed markets. However, efforts to increase screening are expected to identify more aneurysm patients earlier, which expands the diagnosed population and supports future procedure growth.

Countries such as the United Kingdom are increasing screening efforts partly because aneurysm prevalence is expected to rise with aging populations. As more patients are diagnosed, more will enter treatment pathways where stent grafts are considered. This makes screening a meaningful long-term driver for the market.

Market Limiters

Difficult Anatomy

The most important limiter in the global stent graft market is difficult anatomy. The success of a stent graft procedure depends heavily on careful imaging, precise sizing and the match between device design and patient anatomy. Not every patient is anatomically suitable for standard abdominal or thoracic endovascular repair.

Irregular neck anatomy, vessel tortuosity, branch involvement and other structural challenges can limit the feasibility of stent graft procedures. Although modular graft systems and newer fenestrated and branched designs have expanded the number of treatable patients, a meaningful portion of patients still require open surgical repair because endovascular treatment is not anatomically viable or because rupture risk does not allow the time needed for more customized approaches.

This limitation is especially important because it creates a ceiling on how much the market can grow through standard devices alone. Innovation continues to push that ceiling higher, but anatomy remains a central constraint.

Stent Graft Complications

Stent graft complications also continue to limit the market. Compared with open surgery, endovascular aneurysm repair can carry a higher risk of reintervention over the long term. Certain trials, including the DREAM trial, highlighted that EVAR was associated with higher reintervention rates, which has influenced physician thinking and long-term follow-up practices.

There is also concern around aneurysm rupture risk after stent graft placement, particularly if sealing is incomplete or if long-term device performance is compromised. These concerns do not eliminate the appeal of stent grafts, but they do make follow-up imaging and surveillance more important. In some health systems, this can reduce the simplicity of the economic case and influence how physicians select patients.

Complexity of Advanced Cases

A further limiter is the complexity of advanced stent graft cases. Fenestrated and thoracic procedures can offer strong clinical value, but they also require greater procedural planning, more specialized imaging and more technical expertise. This can limit adoption to higher-volume centers or more experienced operators, especially in regions where advanced endovascular infrastructure is less developed.

As a result, market growth in advanced segments may be strong, but not evenly distributed. Adoption depends not only on clinical need, but also on physician training and center capability.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through 2032.

Regional Coverage

North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, competitor benchmarking and product positioning by combining detailed forecasting with practical clinical and commercial context.

Markets Covered and Segmentation

• The report covers the Global Stent Graft Market, further segmented into:

AAA Stent Graft Market

This segment includes devices used in abdominal aortic aneurysm repair, including major component categories used in standard EVAR procedures.

Fenestrated Stent Graft Market

This segment includes advanced graft systems designed for more complex anatomies where branch vessel preservation and customized sealing are important.

TAA Stent Graft Market

This segment includes thoracic aortic aneurysm stent grafts used in TEVAR procedures and other thoracic aortic interventions.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts through 2032 and historical data to 2022. This segmentation reflects the major clinical use areas in which endovascular graft technology continues to expand.

Competitive Analysis

W.L. Gore holds a leading position across multiple segments of the abdominal aortic aneurysm market, including bifurcated main body grafts, contralateral and ipsilateral iliac legs or limbs, and iliac extensions. It also holds a strong second-place position in aortic extension segments. Although the company does not offer an aorto-uni-iliac stent graft, its broader AAA portfolio remains highly influential. Regulatory milestones have also supported its position. The GORE EXCLUDER Iliac Branch System received FDA approval in 2016, while the GORE TAG Thoracic Branch Endoprosthesis received FDA approval in 2022 for high-risk patients requiring left subclavian artery debranching procedures. Gore also received approval for the TAG Conformable thoracic stent system with ACTIVE CONTROL, which supports improved deployment control and sealing in TEVAR.

Medtronic remains one of the most important global competitors through its Endurant II AAA portfolio and its Valiant thoracic stent graft family. In the thoracic segment, Medtronic positions Valiant at a premium price level relative to several competitors. The company strengthened its EVAR and TEVAR position through investment in Arsenal AAA and its acquisition of Aptus Endosystems, which added the Heli-FX and Heli-FX Thoracic EndoAnchor systems. Medtronic also received FDA approval for the Valiant Navion thoracic stent graft system and later expanded the Valiant family into thoracoabdominal use, helping reinforce its role in advanced aortic repair.

Cook Medical remains a major competitor with a broad AAA and thoracic portfolio. Its Zenith Flex and Zenith Renu families give it meaningful presence across standard abdominal components, and the company is especially notable in the fenestrated segment through the Zenith Fenestrated line. That offering has supported strong revenue growth over time, although adoption can be limited by assessment complexity, longer wait times and higher cost. In thoracic repair, Cook markets the Zenith Alpha family, which received FDA approval for isolated descending thoracic aorta lesions. Cook's relatively low per-case ASP also shapes its market position, especially where pricing remains important.

Overall, the competitive landscape is shaped by product breadth, regulatory progress, anatomical reach and the ability to support increasingly complex endovascular repair.

Technology and Practice Trends

A major trend in the global stent graft market is the continued move toward minimally invasive aortic repair. Physicians increasingly prefer endovascular approaches when patient anatomy and clinical condition permit.

Another important trend is the development of more advanced stent graft technologies. Lower-profile devices, improved flexibility, better trackability and more specialized branch and fenestrated systems are making treatment possible in a broader set of anatomies.

Imaging and navigation are also becoming more important. Better pre-procedural planning and more precise deployment support improved outcomes and can reduce complications and reintervention risk.

Finally, the market is moving toward more anatomically tailored treatment. Standard devices remain important, but growth is increasingly supported by more specialized stent graft designs that address complex anatomy and high-risk patient subsets.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

109 pages of detailed market analysis, regional discussion and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the largest and fastest-growing opportunities in the global stent graft market through 2032?

How are thoracic and fenestrated technologies changing the value mix of the market?

What role do screening programs and minimally invasive treatment preferences play in future growth?

How do difficult anatomy and reintervention risk limit the total addressable market for stent grafts?

Which companies hold the strongest positions in AAA, fenestrated and TAA stent grafts, and how are they competing?

How can suppliers align product strategy with the growing need for more precise and more anatomically flexible endovascular repair?

The Global Stent Graft Market Report from iData Research answers these questions with detailed segmentation, pricing analysis, competitive intelligence and market forecasting. Use it to benchmark competitors, evaluate growth opportunities and support strategy in one of the most important vascular intervention device categories.